Medicare Part D Generic Substitution Rates Lower For Higher Cost Brands
Executive Summary
Study sponsored by Association for Accessible Medicines suggests quirks in Part D benefit design and rebating practices are driving the trend.
You may also be interested in...
Policies Targeting ‘Rebate Traps’ In Part D May Not Yield Big Savings, Study Suggests
Research on generic drug coverage in Medicare Part D plans finds access unobstructed for majority of lower cost alternatives. However, study may offer incomplete picture, generic and biosimilar advocates say.
Medicare Part D Redesign Will Lead To Bigger Rebate Demands – MedPAC Panelist
DeRoyal’s DeBusk urges a focus on rebates, while Brookings' Ginsburg wants a focus on design, not savings per se, as MedPAC discusses restructuring the Part D design to better accommodate current market dynamics. Formal recommendations to Congress may be approved in the spring.
Half Of 1st Approved Generics Do Not Launch Due To Part D Formulary Obstacles, AAM Says
Medicare Part D program should place generics on tiers separate from brand drugs and create a dedicated tier for specialty generics and biosimilars, AAM advocates in white paper.